Form 4: Zivo Bioscience Director Alison Cornell Reports Share Acquisitions
SEC Form 4 Filing
Director Alison Cornell of Zivo Bioscience, Inc. reported acquiring 9,797 shares of common stock on January 1, 2025.
Summary
- Alison Cornell, a director at Zivo Bioscience, Inc., reported acquiring 1,516 shares of common stock on January 1, 2025.
- Additionally, Ms. Cornell acquired 8,281 shares of common stock on the same day.
- Both transactions were reported as acquisitions at a price of $0 per share.
- Following these transactions, Ms. Cornell's total direct holdings increased to 267,772 shares.
Sentiment
Score: 6
Explanation: The document is a routine disclosure of insider transactions. While the increased holdings could be seen as positive, the $0 price suggests a non-market transaction, making the overall sentiment neutral.
Positives
- The director's increased stake in the company could be seen as a positive sign of confidence in Zivo Bioscience's future.
Risks
- The acquisition of shares at $0 may indicate a non-market transaction, such as a grant or award, which may not reflect the market value of the stock.
Industry Context
This is a standard SEC Form 4 filing, which is a routine disclosure for company insiders reporting changes in their beneficial ownership of company stock. It is a common practice for directors and officers to receive stock grants or awards as part of their compensation.
Comparison to Industry Standards
- SEC Form 4 filings are a standard practice for all publicly traded companies in the United States.
- The reporting of share acquisitions by directors is a common occurrence and is not unusual in the context of corporate governance.
- The specific details of the transaction, such as the $0 price, suggest a non-market transaction, which is also common for stock grants or awards.
Stakeholder Impact
- The increased holdings by a director may be viewed positively by shareholders, indicating confidence in the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 01/01/2025 | Date of the reported share acquisitions by Alison Cornell. |
| 01/03/2025 | Date of signature on the SEC Form 4 filing. |
Keywords
Zivo Bioscience, insider trading, share acquisition, Alison Cornell, director, common stock, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.